Article | January 1, 2022

Controlling Host Cell Proteins In Drug Development

Source: Cytiva
iStock-1293772880-lab-science-research-scientist-discovery-development

The ability to harness a cell’s innate machinery to produce specific agents was revolutionary for drug development. However, cell-based production methods bring their own caveats, one of which is the presence of host cell proteins (HCPs).

HCPs are a natural by-product of using cellular factories for biomanufacturing and must be removed during the manufacturing process, especially for products intended for therapeutic use. HCP management strategies that lack range, sensitivity, or reproducibility can result in ineffective and unsafe final products.

Explore methods to detect HCPs and how to reduce the risk of unexpected HCPs and maximize the efficiency of your HCP management strategy.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: